Additionally, in both MM BMMCs cultured alone or in combination with SUP-T1 T-cells, treatment with RUX resulted in increased IL-2 expression and CD8 expression, further supporting that inhibition of the JAK/STAT signaling pathway through RUX is capable of reducing the expression of checkpoint proteins; and, therefore, increases the cytotoxic capacity of T-cells against MM tumor cells, potentially limiting tumoral escape and resistance to immune based approaches in MM treatment. Here, CD8A is linked to Miyoshi myopathy.